Driving compliance in fully remote Alzheimer’s trials is complex, ICON Concierge Services makes it possible. In a pre-clinical study with 600+ participants and over 50 ePROs per patient, Concierge direct-to-patient serv...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
ICON makes TIME World's Best Companies list for 3rd year in a row
ICON are once again honoured to be featured on the TIME World's Best Companies list in 2025. Entrants on the list are ranked based on their performance on three key metrics - employee satisfaction, revenue growth and sustainability transparency.
-
Promised land
As global pressures reshape the pharmaceutical and biotech landscape, sponsors are re-evaluating their outsourcing strategies. ICON’s recent survey of industry stakeholders highlights a clear trend toward fit-for-purpose solutions.
-
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
-
What sets oncology biosimilars apart: Anticipating key challenges in the development landscape
Advancements in biologic therapies have greatly improved our ability to treat cancer over the last few decades — but are typically very costly. With patent expirations encompassing numerous notable oncology biologics, opportunities for oncology biosimilar development are abundant.
-
Early-phase study design considerations for long-term follow-up in vaccine clinical trials
ICON experts discuss why strategic early planning is key to long-term follow-up in vaccine trials—driving stronger protocols, regulatory alignment, and meaningful outcomes.
-
What’s evaluated in a stability study?
This article discusses the importance of stability programs in early clinical drug product development.
-
Embracing proactive multi-indication development for metabolic therapies
In this article, ICON expert , Alan Baldridge discusses how multi-indication development strategies are gaining traction, driven by successful trials across diverse diseases and the expansion of type 2 diabetes drugs into obesity and cardiovascular indications.
-
Mind the gap: The need for gender-specific outcome measurement
Women experience significantly more years of poor health than men due to delayed diagnoses and mischaracterized symptoms, despite living longer on average. This health disparity is rooted in systemic gaps in medical research and clinical trial design, particularly in how health outcomes are measured through Clinical Outcome Assessments (COAs).
-
Navigating global regulatory expectations for AI-enabled devices
Despite the increasing use of AI in medical devices and software as medical devices (SaMD), global regulatory authorities are playing catch up to develop appropriate submission channels.
Read the article in Med-Tech Insights.
-
Strategic Commercialisation of Multi-Indication Obesity Therapies: Balancing Early Access, Pricing, and Lifecycle Value
A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline.
